Navigation Links
Statement on FDA's Approval of XENAZINE(R) for the Treatment of Chorea Associated With Huntington's Disease
Date:8/15/2008

NEW YORK, Aug. 15 /PRNewswire/ -- The Hereditary Disease Foundation (HDF) is extremely pleased the U.S. Food and Drug Administration has approved Xenazine, or tetrabenazine, for the treatment of chorea associated with Huntington's disease.

"Chorea is a major cause of disability and death in patients with Huntington's disease. Chorea is not just a mere inconvenience; it can prevent Huntington's disease patients from walking, talking, working, watching television and almost every aspect of one's life. We are ecstatic that, through the approval of Xenazine, patients and families will have the option to take the only drug developed specifically for treating the movements of Huntington's disease," said Nancy Wexler, Ph.D., Higgins Professor of Neuropsychology in the departments of neurology and psychiatry at Columbia University and president of the Hereditary Disease Foundation.

"While we are still hopeful we can some day find a cure, the approval of Xenazine is a breakthrough for the Huntington's disease community," said Dr. Wexler.

The approval of Xenazine marks the first and only FDA-approved treatment for any symptom of Huntington's disease.


'/>"/>
SOURCE Hereditary Disease Foundation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Statement by the Service Employees International Union (SEIU) Concerning Allegations About SEIU Local 6434, United Long Term Care Workers Union
2. Statement of concern on detention of Drs. Kamiar and Arash Alaei by Iranian authorities
3. Statement by Alan Lambert, Scout Executive, National Capital Area Council, Boy Scouts of America (NCAC) Concerning Closure of Goshen Scout Reservation August 3, 2008
4. Pelosi Statement on Congress Sending Consumer Product Safety Legislation to President
5. PCMA Statement on Baucus-Conrad Comparative Effectiveness Legislation
6. AutoGenomics, Inc. Files Registration Statement for Initial Public Offering
7. Pelosi Statement on House Passage of Global AIDS Legislation
8. Cord Blood America CEO Announces Statement Regarding Expansion and Company Valuation
9. Statement Regarding Los Angeles City Attorney Enforcement Action
10. Pelosi Statement on the Death of Dr. Michael DeBakey
11. Newt Gingrich Statement on the Loss of Tony Snow
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... 20, 2017 , ... ATP Science, an Australian-based company focused ... the January ECRM Trade Show in Hilton Head, SC, benefiting from outstanding meetings ... of supplements that keep the body functioning at its peak performance by providing ...
(Date:1/20/2017)... ... January 20, 2017 , ... "TransFlare 4K Mystique comes with 44 colorful ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , TransFlare ... Sensor,TransFlare 4K Mystique lens flare and light leak transitions have a very high-dynamic range ...
(Date:1/20/2017)... , ... January 20, 2017 , ... “The Angel”: ... Lord has set out for each of his children. “The Angel” is the creation ... of Music in New York City, and impassioned writer. , When asked of her ...
(Date:1/20/2017)... ... January 20, 2017 , ... D R Burton Healthcare ... device, was featured in a study indicating superior performance against competitive products in ... of Three Oscillating Positive Expiratory Pressure Devices During Simulated Breathing“ was published in ...
(Date:1/20/2017)... ... ... “Knowledge is God’s Lighthouse”: a moving and colorful collection of prayers that reminds ... published author, Gene Gaapf, a retired truck driver, and a long-time writer, whose published ... high school and have many different titles,” Gaapf mentions about his different works. “I ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... 2017 Research and Markets has announced the ... - Technology, Route Of Administration, End User - Forecast to 2025" ... ... grow at a CAGR of around 7.8% over the next decade ... industry report analyzes the global markets for Advanced Drug Delivery across ...
(Date:1/20/2017)... YORK , January 20, 2017 ... Inc. (NASDAQ: SGYP ), Novo Nordisk A/S (NYSE: ... SCMP ), and Pernix Therapeutics Holdings Inc. (NASDAQ: ... fell on Thursday, January 19 th , 2017, finishing near ... Health Care Index dropped over 0.7%, while shares of health ...
(Date:1/20/2017)... Avillion LLP, a co-developer and financier of late-stage pharmaceutical product candidates, ... Chief Medical Officer. Dr Weinberg will be based in ... ... 17 years as a pharmaceutical and biotech executive with experience ranging ... of his career, he has interfaced with the US Food & ...
Breaking Medicine Technology: